The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.

The revival of psilocybin in psychopharmacological research heralds a potential paradigm shift for treating mood and anxiety disorders, and other psychiatric conditions beyond the psychotic spectrum. This critical review evaluates current evidence on psilocybin's efficacy, juxtaposing potential benefits with the practical aspects of psychedelic-assisted psychotherapy (PAP) and the methodological constraints of existing research.An electronic literature search was conducted using PubMed/MEDLINE, selecting studies published up to December 2023 that explored the clinical use of psilocybin in mood and anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, and substance use disorder.

Pathways to care: Source of referral at first-episode psychosis, a cross-country comparison between Bologna and South London.

Objectives: Pathways to Care (PtC) are useful indicators of how patients access mental healthcare, especially in the context of first-episode psychosis (FEP). We explored how PtC: source of referral, is associated with patients' characteristics and clinical presentation and assessed the cross-country differences of the PtC predictors between South London and Bologna.

Methods: This study included 427 FEP individuals in the context of the European Union Gene-Environment Interactions (EU-GEI) study.

Comparative efficacy of interpersonal psychotherapy and antidepressant medication for adult depression: a systematic review and individual participant data meta-analysis.

Interpersonal psychotherapy (IPT) and antidepressant medications are both first-line interventions for adult depression, but their relative efficacy in the long term and on outcome measures other than depressive symptomatology is unknown. Individual participant data (IPD) meta-analyses can provide more precise effect estimates than conventional meta-analyses. This IPD meta-analysis compared the efficacy of IPT and antidepressants on various outcomes at post-treatment and follow-up (PROSPERO: CRD42020219891).